Trial site
Southampton
Southampton, SO16 6YD, United KingdomNot linked to an institution yet
- 20running trials
- 8closed trials
The trials here
What the 28 trials at this site are about, from their registry records.
- Phase
- Phase 315 trials
- Phase 25 trials
- Phase 13 trials
- Phase 1/21 trial
- Phase 41 trial
- Status
- Active, not recruiting12 trials
- Completed5 trials
- Recruiting5 trials
- Not yet recruiting3 trials
- Withdrawn2 trials
- Terminated1 trial
- Lead sponsor
- AstraZeneca20 trials
- Acerta Pharma BV5 trials
- Arcus Biosciences, Inc.1 trial
- MedImmune LLC1 trial
- University of Liverpool1 trial
Running trials
Recruiting
A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF
NCT07761117· Phase 3· AstraZeneca· Source
Recruiting
MAVRiC Studies 2L Treatment With AV in Patients With CLL/SLL Who Have Relapsed After a Course of BTKi + BCL2i Combination, With or Without Obinutuzumab
NCT07024706· Phase 2· AstraZeneca· Source
Recruiting
AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
NCT07611110· Phase 3· AstraZeneca· Source
Recruiting
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
NCT07011719· Phase 3· Arcus Biosciences, Inc.· Source
Contact: Medical Director
Recruiting
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.
NCT06916806· Phase 1· AstraZeneca· Source
Recruiting
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
NCT06564038· Phase 1/2· AstraZeneca· Source
Active, not recruiting
Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.
NCT06473779· Phase 3· AstraZeneca· Source
Recruiting
An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
NCT05835310· Phase 3· AstraZeneca· Source
Recruiting
Observational Study of Acalabrutinib in Patients With Chronic Lymphocytic Leukaemia in the United Kingdom
NCT05557695· AstraZeneca· Source
Active, not recruiting
Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)
NCT05348577· Phase 3· AstraZeneca· Source
Active, not recruiting
Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer
NCT03732820· Phase 3· AstraZeneca· Source
Active, not recruiting
Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer
NCT03528694· Phase 3· AstraZeneca· Source
Active, not recruiting
To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.
NCT03330847· Phase 2· AstraZeneca· Source
Active, not recruiting
A Study of AZD6738 and Acalabrutinib in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
NCT03328273· Phase 1· Acerta Pharma BV· Source
Active, not recruiting
A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL
NCT02970318· Phase 3· Acerta Pharma BV· Source
Active, not recruiting
Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer
NCT02546661· Phase 1· AstraZeneca· Source
Active, not recruiting
Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)
NCT02477696· Phase 3· Acerta Pharma BV· Source
Active, not recruiting
Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL
NCT02475681· Phase 3· Acerta Pharma BV· Source
Active, not recruiting
An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma
NCT02213926· Phase 2· Acerta Pharma BV· Source
Active, not recruiting
Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma
NCT01843374· Phase 2· MedImmune LLC· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error